Recombinant Cyno/Rhesus IFN-alpha/beta R2 Fc Protein, CF

Recombinant Cynomolgus IFN-alpha/beta R2Fc Chimera (Catalog # 10071-AB) inhibits the anti-viral activity of (Catalog # 8499-IF) The ED50 for this effect is 0.5-3.5μg/mL.

2 μg/lane of Recombinant Cynomolgus Monkey IFN‑ alpha / beta R2 (Catalog # 10071-AB) was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 75-95 kDa and 150-190 kDa, respectively.

• Reactivity: Pm-Cm, RM
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cyno/Rhesus IFN-alpha/beta R2 Fc Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit Type-I IFN-mediated anti-viral activity. The ED₅₀ for this effect is 0.500-3.50 μg/mL in the presence of 30 pg/mL of Recombinant Human IFN‑ beta (Catalog # 8499-IF).
• Source: Chinese Hamster Ovary cell line, CHO-derived IFN-alpha/beta R2 protein
  

  Cyno/Rhesus IFN-alpha R2 (Ile 27-Lys243) Accession # XP_005548871.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005548871.1
• N-terminal Sequence:

  Ile 27

• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 51.4 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 75 - 95 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cyno/Rhesus IFN-alpha/beta R2 Fc Protein, CF

• beta receptor10
• human interferon alpha
• human interferon alpha/beta receptor
• IFNABR
• IFN-alpha binding protein
• IFN-alpha/beta R2
• IFN-alpha/beta receptor 2
• IFN-alpha-REC
• IFNAR2
• IFN-aR2
• IFNARB
• IFNbR2
• IFN-bR2
• IFN-R
• IFN-R-2
• interferon (alpha, beta and omega) receptor 2
• Interferon alpha binding protein
• interferon alpha/beta receptor 2
• interferon-alpha/beta receptor beta chain
• Type I interferon receptor 2

Background

IFN-alpha/beta R2, also known as IFNAR2, is a 100 kDa glycoprotein in the class II cytokine receptor family. These proteins form heterodimeric receptor complexes that transduce signals from the interferon, IL-10, and IL-28 families of cytokines (1, 2). Mature IFN-alpha / beta R2 consists of an extracellular domain (ECD), containing two fibronectin type III repeats, a transmembrane segment, and a cytoplasmic domain. Alternative splicing generates a secreted isoform that corresponds to the ECD as well as a 50 kDa transmembrane isoform with a substituted and truncated cytoplasmic region (3, 4). The short isoform is impaired in its ability to activate signaling molecules and functions as a dominant negative receptor subunit (5-7). The mature ECD of cynomolgus IFN-alpha/ beta R2 shares 93% and 100% amino acid (aa) sequence identity with that of human and rhesus, respectively. IFN-alpha/beta R2, in association with IFN-alpha/beta R1, is required for mediating the antiviral, antiproliferative, and apoptotic effects of the type I interferons IFN-alpha and IFN-beta. IFN-alpha / beta R2 is the principal ligand binding subunit of the receptor. Ligand binding is stabilized by the subsequent association with IFN-alpha / beta R1, resulting in the formation of a signaling ternary receptor complex (8, 9). IFN-alpha / beta R2 is also subject to presenilin-dependent intramembrane proteolysis, resulting in the liberation of nearly the entire ECD as well as the cytoplasmic domain which migrates to the nucleus and can inhibit gene transcription (10). High concentrations of soluble IFN-alpha / beta R2 bind and neutralize IFN-alpha and IFN-beta, while lower concentrations prolong the antiviral activity of circulating IFN-beta but not IFN-alpha (11). Human but not mouse IFN-alpha / beta R2 constitutively associates with STAT4, which may account for species specific differences observed in type I interferon responses (12).

1. Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
2. Pestka, S. et al. (2004) Immunol. Rev. 202:8.
3. Lutfalla, G. et al. (1995) EMBO J. 14:5100.
4. Novick, D. et al. (1995) J. Leukocyte Biol. 57:712.
5. Pfeffer, L.M. et al. (1997) J. Biol. Chem. 272:11002.
6. Gazziola, C. et al. (2005) Int. J. Oncol. 26:129.
7. Kotenko, S.V. and S. Pestka (2000) Oncogene 19:2557.
8. Lamken, P. et al. (2004) J. Mol. Biol. 341:303.
9. Arduini, R.M. et al. (1999) Prot. Sci. 8:1867.
10. Saleh, A.Z.M. et al. (2004) Oncogene 23:7076.
11. McKenna, S.D. et al. (2004) J. Interferon Cytokine Res. 24:119.
12. Tyler, D.R. et al. (2007) Mol. Immunol. 44:1864.

Bioinformatics

• Uniprot:
  • XP_005548871.1()